Immunotherapy

Anito-cel is a novel CAR T-cell therapy for multiple myeloma that reprograms a patient’s T-cells to target BCMA (B-cell maturation antigen). It uses a fully humanized D-domain binder for enhanced uptake, faster release from targets, stronger CAR expression, and lower risk of immune-related complications. In the phase 2 iMMagine-1 trial with 117 heavily pretreated patients, anito-cel achieved […]

A new mRNA vaccine targeting BCMA—a protein highly expressed on multiple myeloma (MM) cells—has shown promising preclinical results. Using lipid nanoparticle (LNP) delivery, the vaccine effectively triggered a strong, specific immune response against MM cells in both lab and mouse studies. Unlike current therapies such as CAR T-cells, which can be limited by T-cell exhaustion

Early findings from the ongoing phase 1/2 AMPLIFY-7P trial suggest that the investigational vaccine ELI-002 7P could represent a breakthrough in treating pancreatic ductal adenocarcinoma (PDAC), one of the most challenging cancers to treat. The vaccine, designed to target multiple $KRAS$ mutations, has shown a strong and consistent ability to stimulate the immune system in

Researchers have created a promising new combination immunotherapy that could improve treatment for ovarian cancer, a disease that often resists standard immunotherapies. The study combines two immune-based treatments to produce a stronger and longer-lasting anti-tumor response. The first component uses engineered T cells that specifically target the folate receptor alpha, a protein found in abundance

Toripalimab-tpzi (Loqtorzi) has been approved as the first and only immunotherapy for recurrent, unresectable, or metastatic nasopharyngeal carcinoma (NPC). It can be used in combination with cisplatin and gemcitabine as a first-line treatment for metastatic or recurrent locally advanced NPC, or as a single drug for patients whose disease has progressed after platinum-based chemotherapy. The

Montanide ISA-51 is a water-in-oil emulsion adjuvant derived from Freund’s incomplete adjuvant and is designed to enhance immune responses in cancer vaccines with lower toxicity. It works by forming an oil depot at the injection site, allowing slow and sustained release of the antigen for prolonged immune stimulation. This process recruits immune cells like dendritic

A new treatment era has begun for patients with relapsed or refractory large B-cell lymphoma (LBCL) following the FDA approval of the CAR T-cell therapies axicabtagene ciloleucel (Yescarta) and lisocabtagene maraleucel (Breyanzi). Both therapies have proven superior to the previous standard treatment of salvage chemotherapy followed by transplant. In major clinical trials, axi-cel showed a

Advanced colon cancer is a growing cause of cancer-related death among young American men, particularly when it spreads to the liver. Liver metastases are highly resistant to current immunotherapies and often recur even after surgery, creating a critical need for new treatment strategies. A recent study identified a novel dual-immunotherapy approach that reprograms the liver

The off-the-shelf immunotherapy OST-HER2 (OST31-164) demonstrated impressive 2-year overall survival results in a phase 2b trial for patients with recurrent, fully resected pulmonary metastatic osteosarcoma. The 2-year overall survival rate reached 75% among evaluable patients (n=36), significantly higher than the historical control rate of 40% (P<.0001). Patients who achieved an event-free survival (EFS) of at

The HIMALAYA phase III study demonstrated that the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) provides a sustained and clinically meaningful overall survival (OS) benefit compared to sorafenib for patients with previously untreated, unresectable hepatocellular carcinoma (uHCC). The 5-year follow-up data established a new survival benchmark in uHCC, showing a 60-month (5-year) OS rate of 19.6% for STRIDE versus